CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Explore patent oppositions filed by Bioverativ Therapeutics against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Last updated on: Aug 7, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

Sodium Chloride Solution For Drug Reconstitution Or DilutionWYETHMay 14, 2020
Proteolytically Cleavable Fusion Protein Comprising A Blood Coagulation FactorCSL BEHRINGDec 13, 2019
Compositions And Methods For Enhancing Coagulation Factor Viii FunctionTHE CHILDRENS HOSPITAL OF PHILADELPHIAAug 21, 2019

Explore Bioverativ Therapeutics's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 7, 2025
Patent NumberGrant DateTitleTotal Oppositions
Jan 24, 2024Optimized Factor Viii Gene1
Jun 29, 2022Cell Line Expressing Single Chain Factor Viii Polypeptides And Uses Thereof2

Top competitors of Bioverativ Therapeutics

List of top competitors of Bioverativ Therapeutics based on patent oppositions.